Bausch + Lomb settles with DOJ for Ista

Article

B+L subsidiary Ista pleads guilty to conspiracy charges in anti-kickback case and agrees to pay $34M in civil and criminal fines.

Rochester, NY-Bausch + Lomb’s subsidiary Ista Pharmaceuticals, Inc. has reached agreement with the U.S. government to resolve civil and criminal allegations against Ista. The settlement involves conduct by Ista that occurred between January 2006 and March 2011, prior to B+L’s acquisition.

Ista has pled guilty to charges of:

• Conspiracy to introduce a misbranded drug in interstate commerce with intent to defraud and mislead

• Conspiracy to violate the anti-kickback statute

As part of the settlement, Ista has agreed to pay approximately $34M in civil and criminal fines, will be prohibited from participating in federal healthcare programs such as Medicare and Medicaid. Ista products Bepreve (bepotastine besilate), Bromday (bromfenac), Istalol (timolol), Prolensa (bromfenac), and Vitrase (hyaluronidase) have been transferred to B+L and are not subject to any exclusion resulting from this settlement and continue to be eligible for reimbursement under those programs.

Bausch + Lomb was aware of the government investigation prior to its acquisition, and has fully cooperated with the government to resolve this matter. The government has acknowledged that it has no knowledge that Bausch + Lomb, any current director or officer of Bausch + Lomb, or any current director or officer of ISTA was party to any conduct related to this case.

Since acquiring Ista in 2012, Bausch + Lomb has integrated its portfolio of products and related operations, and will wind down the Ista entity by the end of the year.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.